Arzoxifene

Phase 3Small molecule

Eli Lilly

Arzoxifene is one of 82 small molecule programs targeting Bone Fracture. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bone FractureActive, not recruiting

Breast CancerActive, not recruiting

OsteoporosisActive, not recruiting

Bone FracturePhase 3

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

OsteoporosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Trodelvy

Gilead

Preclinical

37 2

Halaven

Eisai

Preclinical

38 3

Arzoxifene

Eli Lilly

Phase 3

1 4

Voltaren

Novartis

Preclinical

1 5

Blenoxane

Bristol-Myers Squibb

Preclinical

1 6

Lexiscan

Astellas

Preclinical

1 7

Adenocard

Astellas

Preclinical

1 8

Acupan

YYonsei University

Preclinical

1 9

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 10

Paracetamol

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Osteoporosis2 trials

Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00383422·320 enrolled

A Study of Arzoxifene to Treat Korean Women With Osteoporosis

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00767299·91 enrolled

Treatment1 trial

A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00190697·70 enrolled

Bone1 trial

Effects of Arzoxifene on Bone Mass and the Uterus

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00085956·300 enrolled

Bone Fracture1 trial

Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00088010·9,369 enrolled

Breast Cancer1 trial

LY353381 in Preventing Breast Cancer in Women With Hyperplasia

Completed·UUniversity of Kansas Medical Center·Phase 2·NCT00005879·199 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Arzoxifene. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Arzoxifene compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Arzoxifene. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Eli Lilly

Arzoxifene

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Osteoporosis2 trials

Treatment1 trial

Bone1 trial

Bone Fracture1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News